Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Acquires 10,925 Shares of Stock

Key Points

• Director Eric Sachetta purchased 10,925 Sensus Healthcare shares at an average price of $3.18, investing $34,741.50 and increasing his holdings by 4.99% to 229,943 shares. He also bought shares in two earlier transactions during the same week.
• SRTS shares rose 3.9% to $3.50, but the company recently reported weak quarterly results, including a $0.53 per-share loss versus an expected $0.12 loss and revenue of $2.29 million against $4.60 million in estimates.
• Analyst sentiment remains mixed but leans positive, with an overall “Moderate Buy” rating and an average price target of $5.83; institutional investors and hedge funds own 25.3% of the stock.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta acquired 10,925 shares of the stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $3.18 per share, for a total transaction of $34,741.50. Following the acquisition, the director owned 229,943 shares in the company, valued at $731,218.74. The trade was a 4.99% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.29 per share, with a total value of $31,939.32.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The shares were bought at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Stock Up 3.9%

SRTS stock traded up $0.13 during midday trading on Friday, hitting $3.50. 62,187 shares of the company traded hands, compared to its average volume of 64,747. Sensus Healthcare, Inc. has a twelve month low of $2.66 and a twelve month high of $5.49. The stock has a market capitalization of $57.61 million, a price-to-earnings ratio of -3.72 and a beta of 1.10. The business has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $3.52.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Alliance Global Partners reaffirmed a "buy" rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Wall Street Zen downgraded Sensus Healthcare from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Citigroup reaffirmed a "buy" rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Weiss Ratings lowered Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. Finally, Lake Street Capital reduced their price objective on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $5.83.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Pacific Ridge Capital Partners LLC lifted its position in shares of Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company's stock worth $2,781,000 after acquiring an additional 125,245 shares during the period. Geode Capital Management LLC lifted its position in Sensus Healthcare by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company's stock worth $630,000 after purchasing an additional 5,316 shares during the period. Sachetta LLC boosted its stake in Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company's stock worth $591,000 after buying an additional 9,500 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in Sensus Healthcare in the 4th quarter valued at $513,000. Finally, North Star Investment Management Corp. acquired a new position in shares of Sensus Healthcare in the 1st quarter valued at $500,000. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source